Valued Wealth Advisors’s AbbVie ABBV Stock Holding History

Valued Wealth Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$141K	Buy	560 +72	+15%	+$15.5K	0.05%	60
2026 Q1	$106K	Sell	488 -66	-12%	-$14.6K	0.04%	60
2025 Q4	$127K	Buy	554 +16	+3%	+$3.65K	0.06%	51
2025 Q3	$125K	Sell	538 -16	-3%	-$3.26K	0.06%	53
2025 Q2	$103K	Buy	554 +18	+3%	+$3.35K	0.05%	55
2025 Q1	$112K	Buy	536 +10	+2%	+$1.94K	0.07%	54
2024 Q4	$93.4K	Sell	526 -368	-41%	-$67.7K	0.06%	60
2024 Q3	$177K	Buy	894 +442	+98%	+$82.5K	0.11%	37
2024 Q2	$77.5K	Buy	452 +224	+98%	+$37.1K	0.05%	54
2024 Q1	$41.6K	Buy	228 +120	+111%	+$20.7K	0.03%	78
2023 Q4	$16.1K	Buy	+108	New	+$15.7K	0.01%	91

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Valued Wealth Advisors's ABBV Position: Q2 2026 in Review

Valued Wealth Advisors increased its AbbVie (ABBV) stake by 15% in Q2 2026, buying an estimated $15.5K and bringing the position to 560 shares worth $141K. The position accounts for 0.05% of the portfolio, ranked #60.

Valued Wealth Advisors first reported a position in ABBV in Q4 2023 and has held it in 11 quarters since. The position peaked at $177K in Q3 2024. 4,188 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Valued Wealth Advisors held 560 shares of AbbVie worth $141K as of Q2 2026.
Valued Wealth Advisors bought 72 AbbVie shares in Q2 2026, an estimated $15.5K.
AbbVie made up 0.05% of Valued Wealth Advisors's portfolio in Q2 2026, its #60 holding.
Valued Wealth Advisors first reported a position in AbbVie in Q4 2023 and has held it in 11 quarters since.
Valued Wealth Advisors's AbbVie position peaked at $177K in Q3 2024.
4,188 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Valued Wealth Advisors's 13F filing for Q2 2026, filed 21 Jul 2026.